icon-folder.gif   Conference Reports for NATAP  
 
  HEPDART 2015: Frontiers in
Drug Development for Viral Hepatitis
December 6-10 2015
Wailea, HI
Back grey_arrow_rt.gif
 
 
 
(HepDart) Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients
 
 
  Reported by Jules Levin
 
A Luetkemeyer1, C Cooper2, P Kwo3, K Kowdley4, S Naik5, M Natha5, LM Stamm5, DM Brainard5, M Sulkowski6, S Naggie7
1San Francisco General Hospital, San Francisco, CA; 2The Ottawa Hospital and Regional Hepatitis Program, Ottawa, ON; 3Indiana University, Division of Gastroenterology/Hepatology, Indianapolis, IN; 4Swedish Liver Center, Department of Gastroenterology/Hepatology, Seattle, WA;
5Gilead Sciences, Inc., Foster City, CA; 6Johns Hopkins University School of Medicine, Baltimore, MD; 7Duke Clinical Research Institute, Infectious Diseases Research, Durham, NC
 
AASLD: Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir and HIV Antiretroviral Regimens in Subjects With HCV/HIV Coinfection - (11/16/15)
 
CROI: Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4- (02/27/15)

HepDart1.gif

HepDart2.gif

HepDart3.gif

HepDart4.gif

HepDart5.gif

HepDart6.gif

HepDart7.gif

HepDart8.gif

HepDart9.gif

HepDart10.gif

HepDart11.gif

HepDart12.gif

HepDart13.gif

HepDart14.gif

HepDart15.gif